Larimar Therapeutics/$LRMR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Larimar Therapeutics
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Ticker
$LRMR
Sector
Primary listing
Employees
71
Headquarters
Website
LRMR Metrics
BasicAdvanced
$355m
-
-$2.09
0.91
-
Price and volume
Market cap
$355m
Beta
0.91
52-week high
$6.42
52-week low
$2.22
Average daily volume
1.9m
Financial strength
Current ratio
4.292
Quick ratio
4.196
Long term debt to equity
1.722
Total debt to equity
2.391
Profitability
EBITDA (TTM)
-172.1
Management effectiveness
Return on assets (TTM)
-56.92%
Return on equity (TTM)
-109.83%
Valuation
Price to book
2.25
Price to tangible book (TTM)
2.25
Price to free cash flow (TTM)
-2.059
Free cash flow yield (TTM)
-48.57%
Free cash flow per share (TTM)
-1.651
Growth
Earnings per share change (TTM)
39.98%
3-year earnings per share growth (CAGR)
26.78%
What the Analysts think about LRMR
Analyst ratings (Buy, Hold, Sell) for Larimar Therapeutics stock.
LRMR Financial Performance
Revenues and expenses
LRMR Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs